Nutropin Articles
Serono's Serostim helps lean body mass
5 April 2004
Aventis to see if Lantus reduces CVD risk
1 March 2004
FDA OKs Serono's Zorbtive for SBS
8 December 2003
Serono's Serostim approved in USA for AIDS wasting
8 September 2003
Serono raises 2003 forecast; 2nd-qtr figs
4 August 2003
New use for Pfizer's Genotropin in EU
14 July 2003
Serono slams CPMP decision on Serostim
5 May 2003
Beaufour gets EU Ok for Nutropin AQ
24 March 2003
Emisphere/Lilly trial oral hGH product
12 August 2002
Eli Lilly 2nd-qtr sales decrease 9%
29 July 2002
Serono's cool.click device cleared in EU
10 June 2002
Somatropin OK for GH deficiency: UK NICE
3 June 2002
FDA clears Nutropin AQ Pen
29 April 2002
Serono reports 10.4% 1st-qtr sales increase
29 April 2002
Pharmacia sales take a dip in first quarter
29 April 2002
Serono launches needle-free Serostim in USA
18 February 2002
Pharmacia 4th-qtr profits take a dip but Celebrex still selling well
11 February 2002
Novo's NovoLog receives US approval for use in pumps
7 January 2002
Serono reports disappointing sales
31 October 2001
Pharmacia EPS rises 24% in third quarter
24 October 2001
Extended labeling for Serono's Saizen approved in EU
16 August 2001
Pharmacia earnings up 20%, sales rise 5%
25 July 2001
New drugs lift Lilly's 2nd qtr sales 16%
23 July 2001
New drugs lift Lilly's 2nd qtr sales 16%
20 July 2001
Schwarz sells back hormone rights
8 June 2001
US FDA probes counterfeit drugs
5 June 2001
Serono makes strong start to 2001
2 May 2001
Needle-free hGH approved for HIV in USA
5 April 2001
Pharmacia acquires remainder of Sensus
8 March 2001
Serono tests Serostim in HIV lipodystrophy
20 February 2001
Pharmacia fourth-quarter earnings jump 32%, driven by Celebrex sales
13 February 2001
Rebif pushes Serono sales up 16.2%
23 January 2001
Novo and Pharmacia settle hGH dispute
14 November 2000
Serono third-quarter earnings leap 83%
24 October 2000
EMEA adopts orphan drug designations
22 September 2000
Serono's Serostim is first EU orphan drug
14 September 2000
Serono sees 2nd-qtr net income leap 60%
21 July 2000
Nutropin Depot launched in USA
29 June 2000
Needle-free hGH from Serono approved in USA
26 June 2000
US approval for Novo Nordisk's Norditropin
21 June 2000
Two new therapies for Crohn's studied
2 June 2000
Aventis gains US approval for Lantus
27 April 2000
Pharmacia's EPS up 27% in 1st quarter
26 April 2000
Schwarz Pharma to set up new R&D pacts
3 April 2000
Alkermes to have eight productsin trials by year-end
17 February 2000
Pharmacia & Upjohn and Monsanto both post strong results for 1999
11 February 2000
Lilly, Alkermes team up for pulmonary hGH
9 February 2000
Analysts enthuse about Ares-Serono
4 February 2000
Novo Nordisk settles Lilly patent dispute
2 February 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
$180M lawsuit bill hits Genentech earnings
21 January 2000
Ares-Serono sales hit $1 billion mark
19 January 2000
Genentech's Nutropin Depot approved in USA
29 December 1999
Genentech to settle patent dispute?
18 November 1999
Ares-Serono says sales "on track to exceed $1 billion in 1999"
4 November 1999
P&U continues turnaround, looking for 1999 double-digit growth
29 October 1999
Genentech in patent dispute with University of California
14 October 1999
Roche reducing stake in Genentech
11 October 1999
Pharmacia & Upjohn net income up 47%
2 August 1999
Novo seeks US go-ahead for liquid hGH (updated)
6 July 1999
Novo files for hGH liquid form in USA
2 July 1999
Pharmacia & Upjohn earnings up 17%
5 May 1999
1st qtr net income up 111% at Ares-Serono
30 April 1999
Genentech's 1st qtr product sales leap 42%
15 April 1999
Genentech fined $50 mill by US govt
15 April 1999
Novo liquid hGH approved in Denmark
29 March 1999
Ares-Serono's earnings beat expectations
11 March 1999
P&U posts strong growth for 1998
12 February 1999
Schwarz licenses hGH products
11 February 1999
Ares-Serono posts solid growth in 1998
19 January 1999
Serono Canada's Serostim Approved In Canada
3 December 1998
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
